Regression effect of hepatocyte nuclear factor 4α on liver cirrhosis in rats

Journal of Digestive Diseases

Volumn 14, Issue 6, 2013, Pages 318-327

  Fan, Ting Ting ^a   Hu, Ping Fang ^a   Wang, Jian ^a   Wei, Ji ^a   Zhang, Qing ^a   Ning, Bei Fang ^a   Yin, Chuan ^a   Zhang, Xin ^b   Xie, Wei Fen ^a   Chen, Yue Xiang ^a   Shi, Bin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

Author keywords

Hepatocyte nuclear factors; Liver cirrhosis; MAP kinase signaling system; Matrix metalloproteinases; Tissue inhibitor of metalloproteinases

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALVASCULIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; THIOACETAMIDE; TRANSCRIPTION FACTOR JUND; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CIRRHOSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; CELLS, CULTURED; EXTRACELLULAR MATRIX; HEPATOCYTE NUCLEAR FACTOR 4; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MAP KINASE SIGNALING SYSTEM; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; THIOACETAMIDE;

EID: 84876991981     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12042     Document Type: Article

References (43)

1. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis: definition, nomenclature, and classification. Bull World Health Organ 1977; 55: 521-540.
2. Pinzani M, Rosselli M, Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol 2011; 25: 281-290.
3. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25: 195-206.
4. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011; 6: 425-456.
5. Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010; 7: 425-436.
6. Jiao J, Friedman SL, Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009; 25: 223-229.
7. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002; 122: 1525-1528.
8. Bortolotti F, Guido M. Reversal of liver cirrhosis: a desirable clinical outcome and its pathogenic background. J Pediatr Gastroenterol Nutr 2007; 44: 401-406.
9. Desmet VJ. Comments on cirrhosis reversal. Dig Liver Dis 2005; 37: 909-916.
10. Desmet VJ, Roskams T. Reversal of cirrhosis: evidence-based medicine? Gastroenterology 2003; 125: 629-630; author reply 630-1.
11. Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ. Hepatocyte nuclear factor 4α (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol 2001; 21: 1393-1403.
12. Naiki T, Nagaki M, Asano T, Kimata T, Moriwaki H. Adenovirus-mediated hepatocyte nuclear factor-4α overexpression maintains liver phenotype in cultured rat hepatocytes. Biochem Biophys Res Commun 2005; 335: 496-500.
13. Watt AJ, Garrison WD, Duncan SA. HNF4: a central regulator of hepatocyte differentiation and function. Hepatology 2003; 37: 1249-1253.
14. Parviz F, Matullo C, Garrison WD etal. Hepatocyte nuclear factor 4α controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet 2003; 34: 292-296.
15. Yue HY, Yin C, Hou JL etal. Hepatocyte nuclear factor 4α attenuates hepatic fibrosis in rats. Gut 2010; 59: 236-246.
16. Ning BF, Ding J, Yin C etal. Hepatocyte nuclear factor 4α suppresses the development of hepatocellular carcinoma. Cancer Res 2010; 70: 7640-7651.
17. Yin C, Lin Y, Zhang X etal. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4α gene. Hepatology 2008; 48: 1528-1539.
18. Lin Y, Xie WF, Chen YX etal. Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes. Liver Int 2005; 25: 796-807.
19. Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, Floege J, Gressner AM, Weiskirchen R. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol 2007; 46: 1064-1074.
20. Cao Q, Mak KM, Lieber CS. Leptin represses matrix metalloproteinase-1 gene expression in LX2 human hepatic stellate cells. J Hepatol 2007; 46: 124-133.
21. Smart DE, Green K, Oakley F etal. JunD is a profibrogenic transcription factor regulated by Jun N-terminal kinase-independent phosphorylation. Hepatology 2006; 44: 1432-1440.
22. Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-620.
23. Poynard T, McHutchison J, Manns M etal. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313.
24. Serpaggi J, Carnot F, Nalpas B etal. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 2006; 37: 1519-1526.
25. Bortolotti F, Guido M, Cadrobbi P etal. Spontaneous regression of hepatitis B virus-associated cirrhosis developed in childhood. Dig Liver Dis 2005; 37: 964-967.
26. Farci P, Roskams T, Chessa L etal. Long-term benefit of interferon α therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126: 1740-1749.
27. Issa R, Zhou X, Constandinou CM etal. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004; 126: 1795-1808.
28. Reif S, Aeed H, Shilo Y etal. Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid. J Hepatol 2004; 41: 235-241.
29. Friedman SL. Hepatic fibrosis - overview. Toxicology 2008; 254: 120-129.
30. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218.
31. Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci U S A 1985; 82: 8681-8685.
32. Mann DA, Smart DE. Transcriptional regulation of hepatic stellate cell activation. Gut 2002; 50: 891-896.
33. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-2250.
34. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001; 21: 373-384.
35. de Boer RA, Pokharel S, Flesch M etal. Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. J Mol Med (Berl) 2004; 82: 678-687.
36. 1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways. Am J Physiol Lung Cell Mol Physiol 2007; 293: L790-799.
37. Vepachedu R, Gorska MM, Singhania N, Cosgrove GP, Brown KK, Alam R. Unc119 regulates myofibroblast differentiation through the activation of Fyn and the p38 MAPK pathway. J Immunol 2007; 179: 682-690.
38. Qiang H, Lin Y, Zhang X etal. Differential expression genes analyzed by cDNA array in the regulation of rat hepatic fibrogenesis. Liver Int 2006; 26: 1126-1137.
39. Zhong W, Shen WF, Ning BF etal. Inhibition of extracellular signal-regulated kinase 1 by adenovirus mediated small interfering RNA attenuates hepatic fibrosis in rats. Hepatology 2009; 50: 1524-1536.
40. Takahra T, Smart DE, Oakley F, Mann DA. Induction of myofibroblast MMP-9 transcription in three-dimensional collagen I gel cultures: regulation by NF-κB, AP-1 and Sp1. Int J Biochem Cell Biol 2004; 36: 353-363.
41. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49: 1245-1256.
42. Shah VH, Bruix J. Antiangiogenic therapy: not just for cancer anymore? Hepatology 2009; 49: 1066-1068.
43. Van Steenkiste C, Ribera J, Geerts A etal. Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology 2011; 53: 1629-1640.